Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 3 Risk of incident osteopenia and osteoporosis among breast cancer survivors compared with cancer-free women, stratified by characteristics at diagnosis

From: Evaluation of osteopenia and osteoporosis in younger breast cancer survivors compared with cancer-free women: a prospective cohort study

  Events/person-years Age-adjusted HR (95% CI) MV-adjusted HRa (95% CI)a
Age at diagnosis
 Cancer-free 67/3509 1.00 (reference) 1.00 (reference)
  ≤ 50 years 27/651 2.34 (1.46–3.75) 1.98 (1.21–3.24)
  > 50 years 18/375 1.64 (0.93–2.88) 1.34 (0.75–2.40)
Menopausal status at diagnosis
 Cancer-free 67/3509 1.00 (reference) 1.00 (reference)
 Premenopausal at diagnosis 27/728 1.97 (1.24–3.12) 1.76 (1.09–2.84)
 Postmenopausal at diagnosis 18/298 2.05 (1.15–3.64) 1.58 (0.86–2.89)
ER statusb
 Cancer-free 67/3509 1.00 (reference) 1.00 (reference)
 ER-negative 7/200 1.68 (0.76–3.72) 1.26 (0.54–2.94)
 ER-positive 32/611 2.32 (1.52–3.55) 2.10 (1.34–3.29)
  1. Abbreviations: ER Estrogen receptor, MV Multivariable
  2. aAdjusted for age (years), menopausal status (premenopausal, postmenopausal), bilateral oophorectomy at age < 45 years (yes, no), body mass index (kg/m2), physical activity (MET-h/wk), smoking status (never, ever), alcohol intake (g/d), and hormone replacement therapy (never, ever)
  3. bBreast cancer survivors were restricted to stages I–III